ABSTRACT
INTRODUCTION
Although infrequent, ovarian cancer is the fifth most common cause of death from cancer among women in the USA, excluding non-melanoma skin cancers 1 . Whilst survival rate in women with ovarian cancer has increased since the 1970s, further advances are necessary to improve patient outcome 2 . As far as diagnostic imaging of adnexal masses is concerned, the International Ovarian Tumor Analysis (IOTA) group conducted research of unprecedented accuracy 3 . Since 2005, this group has proposed logistic regression models and ultrasound-based predictive rules (LR1, LR2 and simple rules) for the preoperative characterization of adnexal masses 4, 5 , which have been validated prospectively and externally 6, 7 . IOTA studies have demonstrated that these models have better performance than preexisting predictive risk models, such as the risk of malignancy index (RMI) 7, 8 . More recently, the IOTA group developed a polytomous risk prediction model for more detailed characterization of adnexal masses, the Assessment of Different NEoplasias in the adneXa (ADNEX). This model considers three clinical and six ultrasound features to predict the risk of benign ovarian tumor, borderline ovarian tumor (BOT), Stage I ovarian cancer (OC), Stage II-IV OC and ovarian metastasis 9, 10 . As well as differentiating benign from malignant tumors, the IOTA ADNEX model attempts to identify preoperatively various histological types and extents of tumor spread. This comprehensive classification is clinically important. For example, BOTs confined to the ovary are associated with excellent survival, almost 100% within 10 years. They often affect young women 11 and, indeed, one-third of BOTs are diagnosed under the age of 40 years, when fertility-sparing treatments should be considered 12 . As far as invasive disease is concerned, a meta-analysis showed that women with apparent early-stage OC who underwent laparoscopy had lower rates of complications and shorter hospital stays compared with women who underwent laparotomy, with no significant difference in recurrence rate, although studies with long-term follow-up are still needed to assess recurrence rates and survival outcomes 13 . Conversely, women with ovarian metastasis require highly specific management and usually need additional diagnostic assessment before treatment. Pathological specimens are often obtained from percutaneous biopsy, and primary cytoreductive surgery is indicated in many cases [14] [15] [16] . A diagnostic model that stratifies adnexal masses into four categories according to malignancy might improve triage and be useful for therapeutic decision-making 9 . The aim of this study was to evaluate the performance of the IOTA ADNEX model in the preoperative discrimination between benign ovarian (including tubal and para-ovarian) tumors, BOT, Stage I OC, Stage II-IV OC and ovarian metastasis in a Brazilian gynecological oncology center.
METHODS

Patients
This was a diagnostic accuracy study conducted in the gynecological oncology center of Prof. José Aristodemo Pinotti Women's Hospital, CAISM, Campinas, Brazil. Three hundred and seventy-three women who had been referred to the ovarian pelvic oncology outpatient clinic due to the presence of an adnexal mass were invited consecutively between February 2014 and November 2015 to participate in the study. After pelvic examination, an ultrasound evaluation was scheduled and peripheral blood was collected for serum measurement of tumor marker CA 125. In 196 women, surgery was not indicated due to the benign/functional characteristics of the adnexal mass and they were excluded from the study. These patients were scheduled for sonographic follow-up at 3, 6 and 12 months. If the patient remained asymptomatic and the imaging studies of the mass remained stable or regressed, patients were scheduled for annual follow-up. Forty-six women were excluded from the study for the following reasons: ultrasound scan was performed by examiners not trained in IOTA terms (n = 15), adnexal mass was actually a uterine lesion (n = 11) or an extragynecological tumor (n = 8), doubtful histology of biopsy sample (n = 4), ectopic pregnancy (n = 2), incomplete ultrasound data (n = 2), no measurement of CA 125 (n = 1), > 120 days between the ultrasound scan and surgery (n = 1), previous diagnosis of OC (n = 1) and death before surgery (n = 1). Figure 1 illustrates the enrolment of women into the study. Among the 131 women included, 114 were scheduled for diagnostic and/or treatment surgical procedures and histopathological assessment was carried out by surgical excision of the adnexal mass through laparoscopy or laparotomy. In 17 cases of non-resectable tumors, pathological specimens were obtained from percutaneous biopsy of pelvic mass or abdominal implant. Non-resectable tumors were defined as Stage IIIc or Stage IV OC according to the International Federation of Gynecology and Obstetrics (FIGO) 17 and were deemed not amenable for surgical removal after clinical evaluation by a trained gynecological oncology surgeon. Therapeutic decisions were based on a set of factors: epidemiological and clinical features, subjective assessment in the ultrasound report, biomarkers and, in some cases, magnetic resonance imaging. Pelvic examination, ultrasound assessment, surgery and histological analysis were all performed at this single institution. For histological classification, the guideline of the World Health Organization International Classification of Ovarian Tumors was followed 18 . More than one adnexal mass was detected in 20 women. In cases of multiple masses, the mass with the most complex morphology was included in the statistical analysis. If they presented similar morphology, the largest mass was chosen for inclusion in the study. Written informed consent was obtained from all included women. The study was approved by the University's Research Ethics Committee (protocol no. 008/2010). The STARD statement 19 was followed for reporting the study.
Ultrasound examination
Ultrasound examinations were performed at the Ultrasound Technical Section of CAISM, using a Voluson Expert 730 (GE Healthcare Ultrasound, Milwaukee, WI, USA) or a Toshiba Xsario SSA -660A (Toshiba Medical Systems Corp., Otawara, Japan). Ultrasound examinations were performed by two experienced gynecologists (R.M.J. and K.G.A.) with further training in gynecological ultrasonography. Each had more than 10 years' experience in ultrasound and had performed > 5000 female pelvic ultrasound assessments. R.M.J. obtained his IOTA certificate (London, 2014) before the study commenced. Although K.G.A. obtained her certificate in Leuven, April 2015, she was supervised by R.M.J. during the entire data collection period. In the majority of cases, ultrasound evaluation was performed initially by a transabdominal approach, with the patient's bladder full, then a transvaginal scan, with the patient's bladder empty, was performed. Adnexal masses were described according to IOTA terms and definitions 20 . Color Doppler was applied (pulse repetition frequency = 0.3-0.6 kHz) and a color score (1 = no blood flow; 2 = minimal blood flow; 3 = moderate blood flow; 4 = marked blood flow) was determined. Doppler parameters were not used for the current analysis. For clinical purposes, the nature of the adnexal mass was assessed systematically by subjective assessment on ultrasound as: benign, probably benign, uncertain but more likely benign, uncertain but more likely malignant, probably malignant, malignant. The researchers applied the IOTA ADNEX model a posteriori, just before statistical analysis, without knowledge of the histological results.
CA 125
Serum levels of CA 125 (U/mL) were measured in each patient by the CA 125 II test, which applies the chemoluminescence technique, using an automatic analyzer (Cobas e411; Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer's instructions.
Statistical analysis
We analyzed data using R software (R Core Team, Vienna, Austria) 21 . Statistical calculations were performed using 95% CIs, with P < 0.05 considered to be significant. Sample power for the proposed analyses was 91.7%. The study that introduced the IOTA ADNEX model 9 was published 9 months after commencement of our other study on the accuracy of different IOTA models and RMI. In the present analysis, we used data derived from that study. The IOTA ADNEX model was calculated based on clinical and sonographic data obtained before surgery. However, these calculations were performed a posteriori and IOTA ADNEX results were therefore not available when clinical decisions were made. For the purpose of evaluating the performance of the IOTA ADNEX model, each case was reported based on the following parameters: age (years), type of center (gynecological oncology center for all women in our study), maximum diameter of the lesion (mm), maximum diameter of the largest solid part of the lesion (mm), > 10 locules (yes/no), number of papillary projections (0, 1, 2, 3, > 3) , acoustic shadowing (yes/no), ascites (yes/no) and CA 125 level (U/mL) 9, 10, 20 . All IOTA ADNEX parameters were logged objectively when the ultrasound examination was performed. A data collection sheet in Excel was used. The parameters were entered into an IOTA ADNEX mobile application for each case and the risk stratification was acquired. We compared mean values of the components of the IOTA ADNEX model using Student's t-test or the Kruskal-Wallis test, as appropriate. Sensitivity, specificity and diagnostic odds ratios for the IOTA ADNEX model were calculated at progressive cut-off points for risk of malignancy and at the cut-off point determined by the receiver-operating characteristics (ROC) curve analyses of our data. Areas under the ROC curves (AUC) were determined for different discriminating scenarios. The gold standard was histopathological diagnosis and masses were classified according to the IOTA ADNEX model as benign ovarian tumor, BOT, Stage I OC, Stage II-IV OC or ovarian metastasis.
RESULTS
Histological results of the study group of 131 women with an adnexal mass are provided in Tables 1 and 2 . Sixty-three (48.1%) women had a benign ovarian tumor, 16 (12.2%) had a BOT, 17 (13.0%) had Stage I OC, 24 (18.3%) had Stage II-IV OC and 11 (8.4%) had ovarian metastasis. Among Stage I-IV OC, 80.5% were epithelial, 14.6% originated in the stroma and 4.9% were of mixed histological type. Teratomas were the most frequent benign tumor (31.7%) followed by serous cystadenomas (20.6%).
Clinical and sonographic features of adnexal masses in our study cohort are shown in Table 3 . Women with Stage I-IV OC were significantly older than those with benign, BOT and metastatic tumors. Besides age, the features able to distinguish the category of tumor were serum levels of CA 125, presence of solid tissue within the mass, maximum diameter of the solid tissue, maximum diameter of the solid tissue : maximum diameter of the lesion ratio, > 10 locules and presence of ascites (P < 0.05).
The diagnostic performance of the IOTA ADNEX model is shown by the ROC curve ( Figure 2 ) and the performances at progressive cut-off points for probability of malignancy are presented in Table 4 . For the basic discrimination between benign and malignant tumors, the AUC was 0.92 (95% CI, 0.88-0.97), sensitivity was 88.2% and specificity was 85.7% at an optimal cut-off of 23.6% probability of malignancy. High sensitivity (>90%) was found at cut-offs of 10% and 15%; however, there was an important gain in specificity at a cut-off point of 15% compared with at 10%. Among the most common histological results, considering a cut-off of 15% probability of malignancy, teratomas were classified correctly as benign tumors in 17/20 (85.0%) of the cases, serous cystadenomas in 9/13 (69.2%) and endometriomas in 7/7 (100%). Serous adenocarcinomas were classified correctly as malignant tumors in 20/21 (95.2%) of the cases. Incorrect negative prediction was given for a Stage I serous adenocarcinoma that presented on ultrasound as a 94-mm unilocular cyst in a 75-year-old woman with CA 125 level of 28.4 U/mL. All (5/5) clear cell carcinomas and 4/5 (80.0%) granulosa cell tumors were classified correctly as malignant. The ADNEX model classified correctly 7/7 (100%) cases of serous BOT and 3/6 (50.0%) cases of mucinous BOT as malignant. Table 5 shows the performance of the IOTA ADNEX model in differentiating between the different types of Previous studies have demonstrated that, using subjective ultrasound evaluation, more than 50% of BOT were classified incorrectly as benign or unclassifiable and more than 60% were confused with other histopathological diagnoses 22, 23 . In addition, IOTA simple rules and non-IOTA models had poorer performance for identifying BOT and Stage I OC 5, 8, 24 than did the IOTA ADNEX model in our study. We found that the IOTA ADNEX model did not perform well in discriminating BOT and ovarian metastasis from Stage I OC. Ovarian metastasis is usually confined to the ovaries, and affected women have lower CA 125 levels and are younger in comparison with cases of Stage II-IV OC. Clinical history and subjective assessment of the morphological and Doppler features of the adnexal mass, in addition to non-gynecological findings, are essential when there is suspicion of secondary disease 14, 15 . The preoperative diagnosis of BOT, Stage I OC and ovarian metastasis still remains a challenge in the context of ultrasound-based predictive models.
In our gynecological oncology center, the malignancy rate was similar to that found in IOTA oncology centers, and was approximately 52%. In our study sample, the cut-off for malignancy probability of 15% had a sensitivity of 91.2%, comparable to the 94.5% found by Van Calster et al. in their pooled data analysis 9 . Our specificity of 71.4% was slightly lower than theirs, which 
Figure 2
Receiver-operating characteristics (ROC) curve analysis of performance of International Ovarian Tumor Analysis ADNEX model in discriminating between benign and malignant adnexal masses. Optimal cut-off was 23.6% for probability of malignancy, at which sensitivity was 88.2%, specificity was 85.7%, positive predictive value was 12.9%, negative predictive value was 13.0% and area under ROC curve was 0.925. Cut-offs of 3.0%, 5.0%, 10.0% and 15.0% are also indicated.
was 78.7%. Considering these results, the cut-off value of 15% might be suitable in an oncology center, contributing to the best indication of the surgical method required. In comparison with the pooled data in the original IOTA study 9 , the IOTA ADNEX model in our study showed similar or better performance for distinguishing between benign ovarian tumors vs Stage II-IV OC, benign ovarian tumor vs ovarian metastasis, BOT vs Stage II-IV OC, Stage I OC vs Stage II-IV OC and Stage II-IV OC vs ovarian metastasis.
We noted a significant difference in the maximum diameter of the adnexal masses in our study in comparison with the IOTA ADNEX study, for all types of tumors; mean maximum diameter of benign tumors was 113 mm in our study vs 63 mm in the IOTA study and of Stages II-IV OC was 139 mm in our study vs 85 mm in the IOTA study. This difference could indicate delayed access to tertiary care in the healthcare system of a developing country. The IOTA group found poorer performance of subjective assessment, LR1, LR2, IOTA simple rules and RMI in very small and very large adnexal masses, with the poorest performance found for large tumors with diameter ≥ 10 cm 25 . It is possible that larger tumors are more difficult to image for ultrasound morphological assessment, particularly in the finding of papillary projections, which might have contributed to the marginally lower performance found in our study in comparison with the original one 9 . In our study, acoustic shadowing was 100% associated with benignity and was observed in 30.2% of benign lesions. This sonographic feature is a predictive criterion of benignity in all aforementioned IOTA models 4, 5, 9 . Nevertheless, in a recent study, Timmerman et al. observed that acoustic shadowing was found in 17.4% of benign tumors and in a small number (4.2%) of malignant tumors 26 . A limitation of our study is the relatively small sample, especially for the number of BOT, Stage I OC and ovarian metastasis, which might preclude a reliable conclusion being made concerning the performance of the IOTA ADNEX model in these specific histological types. Moreover, different from the original study that proposed the IOTA ADNEX model, our data were collected in a single gynecological oncology center with a high rate of malignancy, which could introduce bias. Even though ultrasound evaluation was performed by well-trained medical doctors specialized in ultrasonography, it is worth highlighting that these professionals were non-IOTA investigators and that the study was conducted at a center located in a middle-resource country.
In conclusion, the IOTA ADNEX model had good to excellent performance in discriminating different types of ovarian tumors. We consider this model to be a useful diagnostic tool in the management of patients with adnexal masses presenting to a gynecological oncology center. The classification system stratified according to malignancy might allow more accurate triaging of cases. It should also assist in the prioritization of patients for surgery and therapeutic decision-making, adding diagnostic information to cases with an indication for minimally invasive surgery. Further analyses are needed to determine the use of the IOTA ADNEX model by less experienced ultrasound examiners.
